Drug Profile
BMS 751324
Alternative Names: BMS751324Latest Information Update: 02 Mar 2011
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Pharmacopeia Drug Discovery
- Developer Bristol-Myers Squibb
- Class Antirheumatics; Benzamides; Skin disorder therapies; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 30 Jun 2010 No development reported - Phase-I for Rheumatoid arthritis in Canada (PO)
- 30 Jun 2010 No development reported - Phase-I for Rheumatoid arthritis in India (PO)